Open AccessRepository corticotropin injection improves quality metrics in an observational study of multiple sclerosis relapse
Author(s) -
Jeffrey B. Kaplan,
Tamara Miller,
Matthew Baker,
Bryan Due,
Enxu Zhao
Publication year - 2021
Publication title -
neurodegenerative disease management
Language(s) - English
Resource type - Journals
eISSN - 1758-2032
pISSN - 1758-2024
DOI - 10.2217/nmt-2021-0030
Subject(s) - observational study , medicine , depression (economics) , multiple sclerosis , quality of life (healthcare) , clinical trial , neurology , physical therapy , disease , psychiatry , nursing , economics , macroeconomics
Aim: To determine whether clinicians evaluate American Academy of Neurology (AAN) quality metrics for patients with multiple sclerosis (MS) relapse and whether repository corticotropin injection (RCI) improves clinical and patient-reported outcomes associated with these metrics at 2 and 6 months after treatment. Methods: A multicenter, prospective, observational registry evaluating patients receiving RCI for MS relapse (N = 125) categorized data according to AAN quality metrics involving diagnosis, disability, fatigue, cognitive impairment, depression, and quality of life. Results: Clinicians assessed all 11 AAN quality metrics in patients with MS relapse. Disability, fatigue, cognitive impairment, depression, and quality of life outcomes improved with RCI therapy. Conclusion: RCI was associated with improved quality metrics, and AAN guidelines were followed during routine RCI treatment for MS relapse.